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A B S T R A C T
Systemic lupus erythematosus (SLE) is a systemic inflammatory autoimmune disease characterized by a broad
spectrum of clinical and serological manifestations. This may reflect a complex and multifactorial etiology in-
volving several identified genetic and environmental factors, though not explaining the full risk of SLE.
Established SLE risk genotypes are either very rare or with modest effect sizes and twin studies indicate that
other factors besides genetics must be operative in SLE etiology. The exposome comprises the cumulative en-
vironmental influences on an individual and associated biological responses through the lifespan. It has been
demonstrated that exposure to silica, smoking and exogenous hormones candidate as environmental risk factors
in SLE, while alcohol consumption seems to be protective. Very few studies have investigated potential gene-
environment interactions to determine if some of the unexplained SLE risk is attributable hereto. Even less have
focused on interactions between specific risk genotypes and environmental exposures relevant to SLE patho-
genesis. Cohort and case-control studies may provide data to suggest such biological interactions and various
statistical measures of interaction can indicate the magnitude of such. However, such studies do often have very
large sample-size requirements and we suggest that the rarity of SLE to some extent can be compensated by
increasing the ratio of controls. This review summarizes the current body of knowledge on gene-environment
interactions in SLE. We argue for the prioritization of studies that comprise the increasing details available of the
genome and exposome relevant to SLE as they have the potential to disclose new aspects of SLE pathogenesis
including phenotype heterogeneity.
1. Introduction
Etiologies of autoimmune rheumatic diseases are appreciated to be
complex and often multifactorial, involving several genetic factors and
exposures to environmental factors in ways that lead to a large phe-
notypical diversity and remain to be charted. This especially holds true
for systemic lupus erythematosus (SLE), which is a clinically hetero-
genous, multisystem, autoimmune disease characterized by immune
dysregulation, serological changes that include a plethora of auto-
antibodies, immune complex deposition and complement activation,
which eventually lead to tissue injury [1].
At least 90% of patients with SLE are women, the incidence in
African-American females is> 2.5 times higher than in white females
and SLE has the highest incidence rates before the age of menopausal
onset [2,3]. The prevalence of SLE varies between 0.02 and 0.1% in
European and American populations, with an estimated prevalence of
0.045% among Danes [3–6]. Many genetic and environmental factors
have been speculated or shown to influence the varying risks of SLE;
most studies have focused separately on each of these factors to in-
crease our understanding of how they may influence the pathogenesis
of SLE [7–9]. The existence of familial clustering of SLE is illustrated by
the dramatic increase in risk of SLE in close relatives to SLE patients.
Relatives of Danish SLE patients were at a 3-fold, 10-fold, 50-fold and
86-fold increased relative risk of SLE in 2nd degree relatives, 1st degree
https://doi.org/10.1016/j.autrev.2018.11.005
Received 12 November 2018; Accepted 18 November 2018
☆ Supported by grants from the Danish Rheumatism Association (non-commercial) to HCB Leffers (A5094) and S Jacobsen (A3865).
⁎ Corresponding author at: Copenhagen Lupus and Vasculitis Clinic, Center for Rheumatology and Spine Diseases, Rigshospitalet, Section 4242, Blegdamsvej 9, DK-
2100 Copenhagen, Denmark.
E-mail address: sj@dadlnet.dk (S. Jacobsen).
Autoimmunity Reviews 18 (2019) 382–392
Available online 14 February 2019
1568-9972/ © 2019 The Author(s). Published by Elsevier B.V. This is an open access article under the CC BY license 
(http://creativecommons.org/licenses/BY/4.0/).
T
relatives, dizygotic twins or monozygotic twins, respectively [10]. In an
Asian population- and registry-based study the degree of relatedness
was associated with an even more pronounced relative risk of SLE,
where the heritability was estimated to 44% [11]. Genome-wide asso-
ciation studies (GWAS) and observational studies have at present
identified>100 susceptibility genes for SLE, but a meta-analysis of two
Asian GWAS could only explain 28% of the heritability [8]. This is well
in line with population-based SLE twin studies that show concordance
rates of 14%–25% in monozygotic twins [10,12]. This indicates that
risk of SLE is influenced by other factors than genetics only, leaving
environmental exposures as strong candidates for such other factors.
Environmental factors have by several studies been suggested to
significantly impact risk of autoimmune diseases in general [13,14] as
well as in SLE [15]. The contribution of environmental factors to the
risk of SLE has been estimated to constitute 56% [11]. This estimate
does not consider the possibility of biological interactions between the
genome and the full spectrum of exposures, the exposome, that may add
to the risk of SLE. Further, several exposures have been shown to in-
fluence epigenetic mechanism that change gene expression without
altering the underlying DNA sequence [9,16]. These observations sup-
port the notion that identification of specific gene-environment (G-E)
interactions associated with autoimmune diseases including SLE may
hold great promise to chart the sources and pathways that underlie
these diseases with a view to develop disease prevention and inter-
vention strategies [17].
In SLE, however, such interactions have only been investigated in
small cohorts mostly focusing on genes, which are non-specific to SLE,
together with a limited number of exposures [18–23].
The aim of this paper is to review the current knowledge on G-E
interactions as to the risk of SLE and to address some of the challenges
as well as potentials of studying such interactions.
2. Systemic lupus erythematosus
The clinical complexity of SLE is demonstrated by the broad spec-
trum of clinical manifestations, including cutaneous, musculoskeletal,
cardiopulmonary, renal, neurological, and gastrointestinal manifesta-
tions. As for laboratory abnormalities, these may reflect hematological
and immunological aberrations, which are also included in the syn-
drome classification of SLE. Immunological aberrations can be reflected
by serological changes, including increased levels of autoantibodies and
decreased levels of complement in the circulation [24]. At disease
onset, the patients may present in clinical clusters that typically are
characterized by either acute cutaneous, chronic cutaneous or renal
manifestations, i.e. lupus nephritis [25]. During the course of the dis-
ease, the incident development of proteinuria as a marker of lupus
nephritis may be predicted by lymphopenia and a high number of au-
toantibodies, including anti-dsDNA antibodies [26,27]. Presence of
autoantibodies against phospholipids and/or the lupus anticoagulant
delineate another subset of patients with increased risk of thrombotic
events [1,28].
Identifying the time of disease onset remains a crucial challenge as
this may be of pivotal significance in the discrimination between dis-
ease triggering factors and factors that may modify the course of the
disease. It is well recognized that in persons who subsequently develop
SLE, serological changes may predate clinical manifestation of the
disease by>9 years [29,30]. The early autoantibody repertoire does
not epitope-wise seem to differ substantially from the repertoire of es-
tablished disease, i.e. comprising mainly autoantibodies against cellular
and nuclear components, but the number of autoantibodies does in-
crease during the preclinical phase [29] and the activation of the type I
interferon (IFN) system has been shown to predict manifest auto-
immune connective tissue disease in subjects with anti-nuclear anti-
bodies [31].
Activation of the type I IFN system in SLE patients can be initiated
by signaling through Toll-like receptors (TLR) and other nucleic acid-
sensing mechanisms, leading to the production of immune complexes,
looped activation of persistent type I IFN responses, and neutrophil
activation and trapping [1,32]. Endogenous sources of TLR triggers
have been linked to impaired clearing of cellular and nuclear debris
derived from various types of cell death, including apoptosis, due to
various deficiencies of innate immunity [33]. However, it is of interest
that not only extracellular vesicles derived from apoptotic nucleated
cells may have pro-inflammatory effects, but also vesicles shed from
activated platelets [34] with the latter having a rich content of mi-
tochondria containing DNA similar to bacterial DNA due to its high
content of CpG-regions [35]. It does, however, remain to be fully de-
termined, to which extent environmental agents may act as direct
triggers of immune activation and/or have modulating effects hereon in
SLE patients.
Aberrations of innate immunity as well as adaptive immunity may
also impact the clinical course of disease with respect to e.g. nephritis,
thrombosis and infections [36]. Understanding the early events of SLE
may not only provide pathogenetic insight but may also offer oppor-
tunities to attenuate the development of comorbidities, organ damage
and increased mortality attributable to SLE [37] by improving diag-
nostics and avoiding therapeutic delay [38].
2.1. Genetic factors modifying risk of systemic lupus erythematosus
The promising outlook of studying the genome for genetic con-
tribution and risk variants for SLE [8] has been challenged by the fact
that the multitude of identified susceptibility genes confer such low risk
that they do not provide sufficient discrimination to allow rational use
in clinical practice. As for the more strongly associated variants, re-
presenting for example deficiencies of early complement components,
these occur with such rarity that they are seldom encountered in clin-
ical practice. Combinations of genes present in the same individual may
through gene-gene epistatic interaction confer increased risk of SLE
beyond the risk associated with the individual genes, which also holds
true for some gene-sex interactions [39]. The clinical implications of
such genetic findings, including the genetic distinction between various
SLE phenotypes are still in wanting [40]. However, detection of new
variants by whole-genome sequencing and imputations may allow a
substantial increase in the number of recognized common and rare
sequence variants, which as a whole may associate with specific phe-
notype traits as demonstrated for human serum immunoglobulin levels
[41].
Mendelian or monogenic SLE comprises a few rare variants in genes
such as C1Q (complement 1q deficiency) or TREX1 (downregulation of
exonuclease that degrades single- and double-stranded DNA) [42,43].
As suggested by Terruel et al. [44], other rare variants and more
commonly occurring gene variants associated with SLE can be grouped
into clusters that relate to pivotal elements of SLE pathogenesis. Such
clusters can range functionally from innate to adaptive immunity and
homeostatic cellular functions (Fig. 1A).
Autoantigen triggering of TLR 7 by ssRNA nucleotides activates type
I IFN signaling and homozygous variation of TLR7 (rs3853839) is as-
sociated with SLE (2.9% in controls vs. 7.6% in SLE patients in
European populations) and even more with lupus nephritis (14%)
[45,46].
Type I IFN signaling in myeloid and T cells relies in part on signal
transducer and activation of transcription 4 (STAT4) and is also central
in the differentiation of Th1 and Th17 responses [47]. Variation of
STAT4 (rs7574865, frequency of 22% in controls vs. 31% in SLE pa-
tients in the north American population) [47] has been associated with
SLE as well as cardiovascular morbidity in such patients [48,49].
Protein tyrosine phosphatase non-receptor 22 (PTPN22) plays a key
role in several aspects of T cell function and variations of PTPN22
(rs2476601, frequency of 8% in controls vs. 11% in SLE patients in the
European population) has been associated with SLE [50].
The major histocompatibility complex (MHC) belongs to the most
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polymorphic regions of the genome, and is strongly associated with SLE
[51], as also observed in other autoantibody mediated diseases such as
rheumatoid arthritis (RA). In European [52] and North American [53]
populations extended haplotypes susceptible to SLE are HLA-DR2 and
HLA-DR3. Twelve percent of cases vs. 21% of SLE patients and 8% of
controls vs. 17% of cases in a North American population carry these
haplotypes, respectively [53].
2.2. Exposures modifying risk of systemic lupus erythematosus
The concept of integrating life-course exposures to an individual,
from the prenatal period and onwards, and terming such exposures as
an exposome was first published in 2005 [54], and has later been
suggested to encompass the result of the combined exposures from all
sources that reach the internal chemical environment of an individual
[55]. Combined with traditional epidemiological classification of po-
tential external hazards, such as physical, chemical, biological, social
and cultural factors, the concept of an exposome provides a more
complete framework for the understanding and conceptualization of
exposures, being exogenous or endogenous. Such a framework might
improve the overview and understanding of potential roles of various
exposures relevant to the development of SLE as tentatively depicted
(Fig. 1B).
Several environmental exposures have been suggested to be asso-
ciated with the development of SLE. Current smoking, exposure to
crystalline silica and intake of exogenous hormones comprise the
strongest increase in relative risk by a factor 1.5, 2.1–4.6 and 1.5–1.9,
respectively [56–58]. Light to moderate alcohol consumption seems to
be inversely associated with SLE [59]. To this end it is of interest that
smoking may exert pro-inflammatory effects on some parts of
Fig. 1. Genetic and environmental factors influencing the risk of systemic lupus erythematosus (SLE) and how such factors may interact.
A: Genes associated with risk of SLE clustered by which immunobiological functions they may affect, modified from Teruel et al. [8], surviving two different Bayesian
approaches (false positive report probability and Bayesian false discovery probability from a meta-analysis of observational studies by Jeong et al. [112]). Genes in
yellow display rare variants with high prevalence of SLE.
B: Exposures with known or suggested association with SLE. Bold letters: Exposures with confirmed association with SLE. Plain letters: Exposures suggested to
increase risk of SLE but not confirmed [15]. In italics: Other exposures of interest, which have been demonstrated to influence risk of other systemic autoimmune
diseases, i.e. rheumatoid arthritis [93,113].
OCP: Oral contraceptive pill, HRT: Hormone replacement therapy.
C: Framework describing plausible models of interaction between genetic factors and environmental exposures modifying disease risk [85]. Red (1a) and green (1b)
arrows: Genotype and environmental factor influence disease risk independently. Dotted green arrow (2): Genotype changes exposure of environmental factor.
Yellow arrows (3): Genotype changes the expression or impact of the environmental exposure. Violet arrows (4): Environmental factor changes the risk effect of
genotype. Blue arrow (5): Genotype and environmental factor are both required to influence disease risk or phenotype. Numbers in parenthesis correspond with the
numbering in Section 3.1.
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immunopathogenesis and anti-inflammatory effects on other parts
hereof [60].
Pesticides, chemical and industrial exposures have been suggested
to increase risk of SLE by a factor of 1.5–7.4 in various settings [61].
Metabolomic studies have demonstrated a close association between
welding fume exposure and systemic inflammation [62]. It has also
been speculated that several infectious agents may trigger the devel-
opment of SLE and increase the severity of the clinical phenotype; al-
though EBV-associated infectious mononucleosis was not associated
with SLE in a registry-based population study [63,64]. Other evidence
suggest a lack of control of Epstein-Barr virus (EBV) infection in SLE
patients [65]. In clinical practice, it is well-known that ultraviolet (UV)
radiation may exacerbate existing SLE disease and provoke character-
istic skin changes in photosensitive patients [66]. However, the etio-
logical or pathogenic roles of the latter remain to be resolved [66] and
to this part, several other components of the exposome should be
considered and explored as potential factors modifying the risk of SLE.
2.3. Bridging the gap between genome and exposome
The cross-field between the genome and the exposome is enormous
but of even greater interest as it has still not been possible to single out
any environmental or genetic factors that come just near defining a
comprehensive risk model of SLE. However, environmental factors may
interact with genetics by several mechanisms, which may have the
potential to add significantly to such wanted risk models. Epigenetics
are stable and heritable, yet reversible, mechanisms that regulate gene
expression without altering the underlying gene code [67]. One key
epigenetic mechanism is DNA methylation, which controls the acces-
sibility to gene regulatory regions. Aberrant DNA methylation patterns
have been increasingly recognized in SLE patients compared to healthy
controls in epigenome-wide association studies (EWAS). These have
consistently suggested a pattern of DNA hypomethylation of IFN-regu-
lated genes, such as IFI44L, PARP9, IFITM1 and MX1, in CD4+ T cells,
monocytes, granulocytes and B cells [68–72], as well as in white blood
cells (WBCs) in general [73,74]. Differential methylation of WBCs in
SLE patients has even been suggested to be associated with the presence
of SLE-related autoantibodies [75]. Recently, we have further shown
that B cells from Danish SLE twins additionally exhibit a pattern of
promoter hypermethylation best explained by TNF and EP300 as up-
stream regulators, the significance of which is still unknown [72] DNA
methylation is known to vary by sex [76] and ethnicity [77] and may
further be influenced by smoking [78] and nutrition [79]. Interestingly,
the DNA methylation patterns of monozygotic twins have been shown
to diverge throughout life [80], providing further evidence that epi-
genetic factors may contribute to the phenotypic variation observed in
monozygotic twins [72]. Transcription of non-coding RNAs (micro-
RNAs) from intronic regions, which regulate gene expression and
posttranslational modification of histones e.g. acetylation are other
examples of epigenetic factors that are aberrantly expressed in SLE
[81,82].
Recently, it has been demonstrated that EBV produced EBNA2
proteins occupy about half of the SLE susceptibility loci and co-clusters
with transcriptional factors, thereby altering gene expression [83]. This
very intriguing finding implies a new potentially pathogenic role of EBV
in SLE, and the finding need to be corroborated by controlled tran-
scriptomic studies.
2.4. Rationale for studying gene-environment interaction in SLE
Current knowledge indicates a multifactorial risk profile of SLE in-
cluding a multitude of gene variants and several environmental ex-
posures that, however, do not fully account for the total risk of SLE. The
identification of gene-gene interactions and development of gene risk
scores have increased our predictive capacity but still not to an extent
that has direct clinical implication. Unravelling key environmental
triggers in distinct genetically susceptible individuals may provide new
insight into SLE pathophysiology needed for development of new pre-
ventive and therapeutic strategies. Although it seems intuitively ob-
vious that such G-E interactions may contribute to the total risk of SLE,
our current understanding of such interactions is limited as well as the
available data needed for us to reach such an understanding. There is
therefore a large unmet need for studies that comprise genomic and
phenotypic data as well as comprehensive exposure data reaching far
back in time before onset of any subclinical immunological aberrancies
[13]. Encountering this need calls for complex and large datasets spe-
cifically designed to address G-E interactions.
3. Definition and measures of gene-environment interaction
3.1. Gene-environment interaction
In general, studies of G-E interactions aim to describe how genetic
and environmental factors jointly influence the risk of developing
human disease [17]. This includes differential effects on disease risk of
an environmental exposure in persons with different genotypes and vice
versa [84]. To conceptualize relationships between genetic and en-
vironmental factors and their effect on disease risks, Ottman [85] de-
scribed five plausible, not necessarily exhaustive, models of such re-
lationships (Fig. 1C); 1a) genotype and 1b) environmental exposures
influence disease risk independently of each other, e.g. variants of
STAT4 and smoking are both established risk factors for SLE, but have
not yet been shown to display interaction in this respect [21]; 2) the
genotype changes the amount of exposure of an environmental factor,
e.g. common variant in the nicotine acetylcholine receptor gene cluster
associated with nicotine dependency associates with lung cancer [86];
3) the genotype changes the impact of a given environmental exposure,
e.g. higher risk of SLE in smokers who are non-rapid acetylators [20]; 4)
the exposure changes the effect of the genotype, e.g. the influence of
diet on expression of autoimmune-associated genes and disease severity
by epigenetic mechanisms in a murine model of SLE [87]; 5) genotype
as well as exposure are required to raise risk, e.g. development of he-
molytic anemia in glucose-6-phosphate dehydrogenase deficiency
genotype and exposure to certain medications that not otherwise would
cause hemolytic anemia [88]. Each of these models may serve as
scaffolds in the unravelling of SLE pathogenesis by classifying potential
interactions between genetic factors and exposures.
3.2. Interaction
Interaction between two factors is present if the simultaneous oc-
currence or effect of these factors changes the risk of disease from what
would be expected by the effect of each of the factors themselves. The
above described models thus describe relationships that are respec-
tively 1) non-interacting by definition, 2–4) interacting and 5) depen-
dent on occurrence of both factors. Epidemiological studies combining
genetic data with exposure data may provide clues for evaluating the
probability of biological interaction by estimating interaction statisti-
cally. Based on disease rates, i.e. from cohort studies, it is demonstrated
that independent risk factors adhere to an additive risk model and that
biological interaction results in departure from additivity of disease
rates by risk factors [89].
Case-control studies without the dimension of time can instead
provide multiplicative odds ratios. Departure from additivity or multi-
plicativity, may both indicate biological interaction and various mea-
sures of such interaction may be calculated depending on the statistical
model employed [90].
To determine biological interaction in widely used statistical
models, forehand assumption of additive or multiplicative relationship
between independent risk factors is needed and it should be possible to
describe sufficient causes as the complete set of causal mechanisms that
may contribute to causing disease [91]. Sufficient cause is most often
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not a single factor, but a minimum set of factors and circumstances that,
if present in a given individual, will cause the disease [89].
3.3. Measures of biological interaction
Most previous studies of SLE risk association have used a case-
control design, in which the number of cases and controls are de-
termined by investigators and time is not a part of the equation. Here,
odds ratios can be calculated by a variety of methods including logistic
regression analysis. Odds ratios can under the rare disease assumption
approximate relative risks [92], thus allowing approximation of ad-
ditive interaction measures (Table 1), including relative excess risk
(RERI) and attributable proportion (AP) due to interaction as well as
the interaction synergy index (S) as previously described [93]. Multi-
plicative interaction can be expressed as the ratio of odds ratios (ROR)
between the observed odds ratio for combined exposure compared to
that expected by multiplying odds ratios of each exposure. Other ways
to determine statistical interaction include the comparison of statistical
models with and without the interaction in question testing the null
hypothesis that the models perform equally well.
4. Studies of gene-environment risk interactions in systemic lupus
erythematosus
Given the rationale for identifying potential G-E interactions in SLE,
surprisingly few studies have addressed this. Some G-E interactions in
SLE have been suggested, although these have mainly been suggested
by studies of G-E interactions in other diseases [94]. These comprise
interactions between certain environmental factors and variations in
genes encoding xenobiotic-metabolizing enzymes, e.g. N-acetyl-
transferase 2 (NAT2) and glutathione S-transferase M1 (GSTM1), as
well as the protein coding gene of estrogen receptor alpha (ESR1). Also,
two genes with more direct immunological significance have been in-
vestigated, namely the candidate risk gene, STAT4, alongside
TNFRSF1B as summarized below and in Table 2.
4.1. Slow acetylation activity - smoking and dietary habits
Studies in the 1970s revealed a predominance of individuals with
slow acetylation activity among patients with drug-induced SLE
[95,96]. In a case-control study of 152 Japanese SLE-patients, the
modifying effect of polymorphisms in the NAT2 gene on history of
smoking, alcohol- and caffeine-rich beverage intake was investigated
[21,23]. Subjects were divided by genotype into rapid acetylators
(NAT2*4 homozygous) and non-rapid acetylators (NAT2*4 non-homo-
zygous). One analysis suggested an increase in risk of SLE in smoking
subjects that were non-rapid acetylators by an odds ratio of 6.44
compared to the non-smoking rapid acetylators with an AP of 0.5, in-
dicating that half of the total added risk studied was explained by
interaction. However, the ROR was not statistically significant. This
discrepancy might be explained by the faulty assumption that odds
ratios may approximate the relative risk in that study. In further ana-
lyses, a history of alcohol consumption was found to interact with non-
rapid acetylation associating negatively to SLE, whereas non-rapid
acetylators who had a history of drinking black tea were positively
associated with SLE. No interactions were detected for drinking coffee
or black tea.
4.2. Xenobiotic metabolization - smoking and sun exposure
In the above mentioned Japanese population, variants in other
genes encoding enzymes responsible for metabolizing xenobiotics were
also investigated, such as CYP1A1 encoding a cytochrome P450
monooxygenase and GSTM1. Phase 1 enzymes, such as CYP1A1 meta-
bolically activate carcinogenic or toxic substances in cigarette smoke to
highly reactive electrophiles that can be detoxified by phase 2 enzymes
such as glutathione S-transferases. Balance between phase-1 and -2
enzymes could therefore be speculated to influence select elements of
the exposome relevant to the development of SLE. In that study, the AP
was 0.60 for ever-smoking combined with CYP1A1 rs4646903.
However, interaction on a multiplicative scale was not observed. No
interaction measures between history of smoking and GSTM1 null were
found to be statistically significant. Combining these two risk genotypes
with smoking provided an AP of 0.68 to the risk of SLE, but again no
interaction on a multiplicative scale was observed [19].
Another case-control study, comprising 243 SLE cases from North-
and South Carolina, USA, investigated three enzymes of the glutathione
S-transferase family (GSTM1, GSTT1 and GSTP1) as to their possible
interaction with sun exposure [22]. Sun exposure was determined as
occupational sunlight exposure defined as working> 24months in a
sun exposed job. Overall, no interactions were detected. However, in a
subset of Caucasians with GSTM1 null, an OR of 3.1 (95% CI: 0.9–10.8)
was determined. A likelihood ratio test of statistical models with and
without the interaction was not able to retain the null-hypothesis, for
which reason it was concluded that there might be an interaction. Al-
though the effect size of this interaction was not stated, it must be ex-
pected to be low based on the data.
4.3. Estrogen receptor alpha - smoking and alcohol
Given that 80–90% of SLE occurs in women, variants of the gene
encoding estrogen receptor alpha, ESR1, have also been investigated in
SLE [18]. Variations in ESR1 have been studied in many diseases and
found to be associated with e.g. breast cancer and endometrial cancer
[97]. In a Chinese case-control study comprising 230 SLE patients, the
combined presence of ESR1 rs2234693 C-allele and current smoking
history was positively associated with SLE with an odds ratio of 2.5
(Table 2). Presence of interaction was determined by comparing models
Table 1
Statistical methods and measures to indicate biologic interaction.
Measure Interpretation Null hypothesis
Additive interaction RERI: relative excess risk due to interaction Additional risk compared to the expected risk from adding the risk
for each exposure
RERI=0
AP: Attributable proportion due to interaction Proportion due to interaction of overall risk among those with both
exposures
AP=0
S: Synergy index Excess risk from combined exposures relative to the risks from each
exposure
S=1
Multiplicative interaction ROR: Ratio of odds ratios Additional risk compared to the expected risk from multiplying
risks of each exposure
ROR=1
Other methods of indicating
interaction
Comparison of likelihood ratio statistics between
models with and without interaction term
The model with the interaction term is a better fit with the data, and
thus that interaction should be considered
Models are equally
good
Generalized multifactor dimensionality reduction.
Test of significance of identified model.
A measure of the degree of consistency with which the selected
interaction is identified as the best model among all possibilities
considered
Models are equally
good
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in a generalized multifactor dimensionality reduction. As for the like-
lihood ratio test, the effect size of the interaction could not be quanti-
fied. Only a statistically non-significant tendency towards interaction
between this allele and alcohol was observed [18].
4.4. STAT4 and TNFRSF1B variants - smoking
Variations in STAT4 and TNFRSF1B have been studied in the same
Japanese cohort of 152 SLE patients mentioned above as to their po-
tential interaction with smoking. TNF plays a crucial role in a wide
variety of proliferative responses, inflammatory effects and immune
responses and tumor necrosis factor receptor superfamily, member 1B
TNFRSF1B has furthermore been proposed to play a role in apoptotic
mechanisms [98]. The central role of STAT4 as part of type 1 IFN sig-
naling is well established and these genes were therefore of interest to
study, however, it was not stated which specific mechanism of inter-
action that was hypothesized. The AP was found to be 0.49 for
TNFRSF1B rs1061622 in combination with history of smoking, but
presence of interaction was not supported in a multiplicative model.
Nor did STAT4 rs7574865 seem to interact with history of smoking
[21].
5. Challenges in determining gene-environment interactions in
SLE
5.1. Causation
Causation of disease has multiple definitions in the epidemiologic
literature and are suggested to comprise production of effect, necessary
cause, sufficient cause, probabilistic cause and counterfactual cause
[99]. Cause of disease has widely been defined as an event, condition or
characteristic that preceded the disease event and without which the
disease event either would not have occurred at all or would not have
occurred until some later time [100]. For epidemiological associations
to be indicative of causation, they should be supported by observations
that align with principles of causation as for example Hills criteria for
infection [101] or by direct experimental study of disease mechanisms.
Furthermore, a given disease can be caused by more than one causal
mechanism, which may involve the joint action of a multitude of
components; the complexity of which, renders the study of most bio-
logical effects unresolved [91]. As mentioned earlier, tobacco smoking
is associated with SLE, but is by itself not a sufficient cause as smoking
will not cause SLE in everyone [100]. Given the currently obscure and
multifactorial nature of the pathogenesis of SLE, it does not seem fea-
sible to identify the complete set of causal mechanisms that sufficiently
explain the disease risk [91]. In complex disease it therefore seems
more feasible to operate with a probabilistic cause definition [99].
Making causal inferences based on epidemiological studies of G-E in-
teractions limited to only conveying associations may seem futile.
However, the experience in RA, where epidemiological observations of
increased risk conferred by smoking exposure and presence of distinct
MHC haplotypes lead to the unravelling of a central disease mechanism
of seropositive RA serves as an encouraging story. Peptide citrullination
induced by smoking, restriction by HLA-DR shared epitope and pro-
duction of autoantibodies against citrullinated peptides (ACPA) are
now well-established components of RA pathogenesis [102,103]. As-
suming causality, the AP of smoking among carriers of HLA-DR shared
epitope to the risk of ACPA positive RA is estimated at 36% [104].
5.2. Study design
Cohort studies, in which large populations are followed pro-
spectively, may provide concise information on common exposures and
demographic factors before individuals develop overt clinical disease.
This offers low selection and recall bias and provides direct estimates of
incidence rates. However, for rare sequence variants and rare
phenotypical presentations as is the case in SLE, very large cohorts are
required to achieve adequate statistical power. Case-control studies
may thus provide a more direct approach towards studying G-E influ-
ences and interactions on the risk of SLE. The case-control design offers
the opportunity to model and size case-control groups and even to in-
clude relatives of cases as controls in the design [85]. In spite of pitfalls
such as susceptibility to recall bias and selection bias [93] the possi-
bility to impute even long haplotypes for close and distant non-geno-
type relatives in large sample sets may convert the case-control data set
to allow cohort type of analyses [105].
5.3. Study power
Sample-size requirements for G-E studies can be enormous as de-
tection of a statistical interaction may require four times the sample size
for detecting a main effect of comparable magnitude [94,106]. Sample
sizes of thousands of cases are typically needed for interaction analyses
in candidate-gene studies, and tens of thousands may be needed in
GWAS, because of the stringent significance levels required to over-
come inflated type 1 error rates using various correction methods, such
as Bonferroni correction or false discovery rates [106,107]. It might be
speculated whether these conservative correction approaches combined
with the rapidly increasing amount of data produced by various omics
technologies and data sources may prevent us from making new dis-
coveries. This highlights the need for new analytic approaches to “big
data” while considering the opportunity to increase the precision by
which phenotype and disease classification can be made; hereby power
of G-E interaction studies may be increased by better case discrimina-
tion [108].
5.3.1. Increasing statistical study power
Key determinants of statistical power in case-control studies of G-E
interaction are allele frequency, exposure frequency, odds ratios for the
main effects, the magnitude of interaction to be detected, choice of
acceptable levels for type 1 and 2 errors, and sample size [109]. In
diseases where case sample size may be limited due to rarity of the
disease as is the case in SLE, statistical power of such studies can be
increased by increasing the ratio of controls against cases [110]. To
illustrate this, we performed simulations of statistical power [111] of a
fictive case-control study aiming to detect statistical interaction be-
tween a STAT4 variant and exposure to smoking on the risk of SLE,
Fig. 2. Statistical power in simulated case-control studies of a gene-environ-
ment interaction. Power simulations were performed using the following set-
tings: estimated odds ratio for SLE of 1.5 for current smoking (prevalence of
22%, The Danish Health Authority, 2018); estimated odds ratio for SLE of 1.5
for carriage of polymorphism of STAT4 (prevalence of 31% [47]); ratio of odds
ratios= 2; type 1 error= 0.05. Unbroken and dotted lines represent simulation
products for case:control ratios of 1:1 and 1:10, respectively. The vertical lines
indicate the corresponding number of cases needed to achieve 80% power
(horizontal line). MAF: Minor allele frequency.
H.C.B. Leffers, et al. Autoimmunity Reviews 18 (2019) 382–392
389
(Fig. 2). The upper and lower curves representing 1:1 and 1:10 case:-
control ratios, respectively, clearly demonstrate how the increase in
number of controls left-shifts the curves towards higher statistical
power. In this simulation, increasing the number of controls by a factor
10 more than halved the number of cases needed; alternatively, this
approach may also allow regulation of other determinants of statistical
power towards more critical levels.
6. Conclusions and future directions
Over the past several years there has been increasing progress made
in elucidating potential genetic and environmental factors, which
contribute to the development of SLE in individual populations. GWAS
studies have identified numerous candidate susceptibility genes and
large cohort studies have suggested several environmental exposures,
which may influence disease risk. However, no single gene (or combi-
nation of genes) nor the spectrum of exposures of an individual has yet
emerged, which can account for more than a minor fraction of those
who go on to develop SLE. The limited ability of common variants to
account for the genetic contribution to complex disease has prompted
searches for rare gene variants with large cumulative effects, to partly
assess components of the currently obscure part of genetic heritability.
Scientists have long postulated that it is a combination of both ge-
netic and environmental risk factors that confer the greatest risk for SLE
development, and potentially the most influential mechanisms con-
tributing to SLE risk is through synergistic G-E interactions. The study
of G-E interactions in SLE also holds an enormous potential to dissect
into the pathophysiologic processes of SLE and may pinpoint areas of
interest for further exploration of epigenetics and gene expression
studies as for example suggested for IFN signaling in SLE. Given what
we know about G-E interactions in other autoimmune conditions, it is
credible to assume such interactions exist that influence SLE risk and
pathogenesis. The known profound risk association for RA in smokers
with distinct MHC haplotypes has provided significant understanding
into disease pathogenesis as well as providing a potential for RA pre-
vention in high risk individuals. As a promising outlook, G-E interaction
discoveries may have the potential to provide valuable knowledge into
modifiable risk behaviors, which contribute to disease risk in predis-
posed individuals.
The broad heterogeneity of SLE, however, remains a significant
challenge to discovering such G-E interactions as does the relative rarity
of the disease in the general population. Studies that have attempted to
look at candidate G-E interactions in SLE have mostly all suffered from
lack of statistical power due to the relative rarity of specific genetic
factors in combination with defined environmental exposures.
Determining the existence of any such interactions thus calls for alter-
nate and optimized models of discovery. As outlined in this paper, one
such approach is through case-control studies where statistical power is
increased by increasing the ratio of controls to cases. Such strategies, as
well as ongoing efforts to better subclassify specific clinical phenotypes
of SLE and determine more homogeneous case populations, may pro-
vide more clear insights to specific G-E interactions, which influence
disease development. As continued emerging candidate genes and
combinations hereof become better elucidated along with specific ex-
posal patterns, then defined SLE subset populations could be examined
in novel designed case-control studies such as here proposed.
Faced with the complexity of SLE, the need to combine epidemio-
logical and genetic research methods is apparent and can help to pro-
vide better insight into complex pathway mechanisms accounting for
disease heterogeneity and different phenotypes. Such insight might
even have the potential to form base of new approaches for disease
classifications based on specific molecular pathology rather than crude
clinical presentations. Pointing out key pathophysiological processes
would also indicate future directions for the development of new di-
agnostic tools and personalized therapeutic approaches.
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